Developing Novel Therapeutics for HPV-Related Diseases

We develop creatively designed therapeutics that dramatically improve health outcomes for patients suffering from diseases caused by HPV and other viruses.

Antiva in the

July 10, 2018

Antiva Biosciences Closes $15 Million Series C-1 Financing Read more

March 28, 2017

Antiva Biosciences Closes $22 Million Series C Financing Read more

August 6, 2015

Antiva Biosciences Raises $16 Million Series B Financing to Advance Lead Compound for Human Papillomavirus Infections Read more